<H1>Supplementary References
<REFJ>Aberg-Wistedt A, Agren H, Ekselius L, Bengtsson F, Akerblad AC (2000) Sertraline vs. paroxetine
in major depression: clinical outcome after six months of continuous therapy. J Clin
Psychopharmacol 20:645–652.
<REFJ>Aguglia E, Casacchia M, Cassano GB, Faravelli C, Ferrari G, Giordano P, Pancheri P, Ravizza L,
Trabucchi M, Bolino F, et al. (1993) Double-blind study of the efficacy and safety of sertraline vs.
fluoxetine in major depression. Int Clin Psychopharmacol 8:197–202.
<REFJ>Allard P, Gram L, Timdahl K, Behnke K, Hanson M, Sogaard J (2004) Efficacy and tolerability of
venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month
comparative trial with citalopram. Int J Geriatr Psychiatry 19:1123–1130.
<REFJ>Alves P, Cachola I, Brandao J (1999) Efficacy and tolerability of venlafaxine and fluoxetine in
outpatients with major depression. Prim Care Psychiatry 5:57–63.
<REFJ>Baca E, Gonzalez de Chavez M, Garcia-Toro M, Perez-Arnau F, Porras-Chavarino A (2003)
Sertraline is more effective than imipramine in the treatment of non-melancholic depression:
results from a multicentre, randomized study. Prog Neuropsychopharmacol Biol Psychiatry
27:493–500.
<REFJ>Behnke K, Sogaard J, Martin S, Bauml J, Ravindran AV, Agren H, Vester-Blokland ED (2003)
Mirtazapine orally disintegrating tablet vs. sertraline: a prospective onset of action study. J Clin
Psychopharmacol 23:358–364.
<REFJ>Benkert O, Grunder G, Wetzel H, Hackett D (1996) A randomized, double-blind comparison of a
rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and
melancholia. J Psychiatr Res 30:441–451.
<REFJ>Benkert O, Szegedi A, Philipp M, Kohnen R, Heinrich C, Heukels A, van der Vegte-Senden M,
Baker RA, Simmons JH, Schutte AJ (2006) Mirtazapine orally disintegrating tablets vs.
venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of
antidepressant response in patients with major depressive disorder. J Clin Psychopharmacol
26:75–78.
<REFJ>Bennie EH, Mullin JM, Martindale JJ (1995) A double-blind multicenter trial comparing sertraline
and fluoxetine in outpatients with major depression. J Clin Psychiatry 56:229–237.
<REFJ>Bersani G, Rapisarda V, Ciani N, Bertolino A, Sorge G (1994) A double-blind comparative study
of sertraline and amytriptiline in outpatients with major depressive episode. Hum Psychopharm
Clin 9:63–68.
<REFJ>Bielski RJ, Ventura D, Chang CC (2004) A double-blind comparison of escitalopram and
venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry
65:1190–1196.
<REFJ>Bondareff W, Alpert M, Friedhoff AJ, Richter EM, Clary CM, Batzar E (2000) Comparison of
sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J
Psychiatry 157:729–736.
<REFJ>Boyer P, Danion JM, Bisserbe JC, Hotton JM, Troy S (1998) Clinical and economic comparison of
sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a
primary-care setting in France. Pharmacoeconomics 13(1 Pt 2):157–169.
<REFJ>Brenner R, Azbel V, Madhusoodanan S, Pawlowska M (2000) Comparison of an extract of
hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot
study. Clin Ther 22:411–419.
<REFJ>Clerc GE, Ruimy P, Verdeau-Palles J (1994) A double-blind comparison of venlafaxine and
fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French
Inpatient Study Group. Int Clin Psychopharmacol 9:139–143.
<REFJ>Coleman CC, Cunningham LA, Foster VJ, Batey SR, Donahue RM, Houser TL, Ascher JA (1999)
Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison
of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 11:205–215.
<REFJ>Costa e Silva J (1998) Randomized, double-blind comparison of venlafaxine and fluoxetine in
outpatients with major depression. J Clin Psychiatry 59:352–357.
<REFJ>Croft H, Settle Jr. E, , Houser T, Batey SR, Donahue RM, Ascher JA (1999) A placebo-controlled
comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release
bupropion and sertraline. Clin Ther 21:643–658.
<REFJ>Cunningham LA (1997) Once-daily venlafaxine extended release (XR) and venlafaxine immediate
release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann Clin
Psychiatry 9:157–164.
<REFJ>Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE,
Hearst E (1994) A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin
Psychopharmacol 14:99–106.
<REFJ>Davidson JRT, Gadde KM, Fairbank JA, Ranga Rama Krishnan K, Califf RM, Binanay C (2002)
Effect of hypericum perforatum (St John’s Wort) in major depressive disorder: a randomized
controlled trial. JAMA 287:1807–1814.
<REFJ>De Nayer A, Geerts S, Ruelens L, Schittecatte M, De Bleeker E, Van Eeckhoutte I, Evrard JL,
Linkowski P, Fossion P, Leyman S, Mignon A (2002) Venlafaxine compared with fluoxetine in
outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol 5:115–120.
<REFJ>Dierick M, Ravizza L, Realini R, Martin A (1996) A double-blind comparison of venlafaxine and
fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol
Psychiatry 20:57–71.
<REFJ>Doogan DP, Langdon CJ (1994) A double-blind, placebo-controlled comparison of sertraline and
dothiepin in the treatment of major depression in general practice. Int Clin Psychopharmacol
9:95–100.
<REFJ>Eker SS, Akkaya C, Akgoz S, Sarandol A, Kirli S (2005) Comparison of reboxetine and sertraline
in terms of efficacy and safety in major depressive disorder. Turk Psikiyatri Derg 16:153–163.
<REFJ>Ekselius L, von Knorring L, Eberhard G (1997) A double-blind multicenter trial comparing
sertraline and citalopram in patients with major depression treated in general practice. Int Clin
Psychopharmacol 12:323–331.
<REFJ>Fang Y, Yuan C, Xu Y, Chen J, Wu Z, Cao L, Yi Z, Hong W, Wang Y, Jiang K, Gao K, Cui X,
Nierenberg AA (2010) Comparisons of the efficacy and tolerability of extended-release
venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind,
randomized pilot study in a Chinese population. J Clin Psychopharmacol 30:357–364.
<REFJ>Fava M, Hoog SL, Judge RA, Kopp JB, Nilsson ME, Gonzales JS (2002) Acute efficacy of
fluoxetine vs. sertraline and paroxetine in major depressive disorder including effects of baseline
insomnia. J Clin Psychopharmacol 22:137–147.
<REFJ>Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS (1996) Nefazodone vs. sertraline in
outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function
and satisfaction. J Clin Psychiatry 57(Suppl. 2):53–62.
<REFJ>Finkel SI, Richter EM, Clary CM (1999) Comparative efficacy and safety of sertraline vs.
nortriptyline in major depression in patients 70 and older. Int Psychogeriatr 11:85–99.
<REFJ>Forlenza OV, Stoppe Junior A, Hirata ES, Ferreira RC (2000) Antidepressant efficacy of sertraline
and imipramine for the treatment of major depression in elderly outpatients. Sao Paulo Med J
118:99–104.
<REFJ>Fournier JP, Lane RM, Chouinard G, Watson DB, Amin M, Remick RA, Thorpe LU (1999) A
double-blind comparison of sertraline and imipramine in outpatients with major depression: acute
(8 weeks) and continuation (16 weeks) Treatment. Hum Psychopharmacol 12.
<REFJ>Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG,
Morgan L, Lohr KN (2008) Comparative benefits and harms of second-generation antidepressants:
background paper for the American College of Physicians. Ann Intern Med 149:734–750.
<REFJ>Gasto C, Navarro V, Marcos T, Portella MJ, Torra M, Rodamilans M (2003) Single-blind
comparison of venlafaxine and nortriptyline in elderly major depression. J Clin Psychopharmacol
23:21–26.
<REFJ>Gentil V, Kerr-Correa F, Moreno R, D’Arrigo Busnello E, De Campos JA, Juruena MF, Lafer B,
Moreno DH, De Cassia Rodrigues RL, Tiosso A, Benedictis E (2000) Double-blind comparison of
venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. J
Psychopharmacol 14:61–66.
<REFJ>Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger Jr. JT, Krishnan KR,
van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison
WM, Barton D, McLvor M (2002) Sertraline treatment of major depression in patients with acute
MI or unstable angina. JAMA 288:701–709.
<REFJ>Guelfi JD, White C, Hackett D, Guichoux JY, Magni G (1995) Effectiveness of venlafaxine in
patients hospitalized for major depression and melancholia. J Clin Psychiatry 56:450–458.
<REFJ>Guelfi JD, Ansseau M, Timmerman L, Korsgaard S (2001) Mirtazapine vs. venlafaxine in
hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol
21:425–431.
<REFJ>Hewett K, Gee MD, Krishen A, Wunderlich HP, Le Clus A, Evoniuk G, Modell JG (2010)
Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of
bupropion XR and venlafaxine XR. J Psychopharmacol 24:1209–1216.
<REFJ>Hsu JW, Su TP, Huang CY, Chen YS, Chou YH (2011) Faster onset of antidepressant effects of
citalopram compared with sertraline in drug-naive first-episode major depressive disorder in a
Chinese population: a 6-week double-blind, randomized comparative study. J Clin
Psychopharmacol 31:577–581.
<REFJ>Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, Rybakowski JK, QueraSalva MA, Wirz-Justice AM, Picarel-Blanchot F, Bayle FJ (2010) Efficacy of the novel
antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety
symptoms in patients with major depressive disorder: a randomized, double-blind comparison
with sertraline. J Clin Psychiatry 71:109–120.
<REFJ>Kavoussi RJ, Segraves RT, Hughes AR, Ascher JA, Johnston JA (1997) Double-blind comparison
of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 58:532–
537.
<REFJ>Keller MB, et al. (2007) The prevention of recurrent episodes of depression with venlafaxine for
two years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry
62:1371–1379.
<REFJ>Khan A, Fabre LF, Rudolph R (1991) Venlafaxine in depressed outpatients. Psychopharmacol Bull
27:141–144.
<REFJ>Khan A, Upton GV, Rudolph RL, Entsuah R, Leventer SM (1998) The use of venlafaxine in the
treatment of major depression and major depression associated with anxiety: a dose-response
study. Venlafaxine Investigator Study Group. J Clin Psychopharmacol 18:19–25.
<REFJ>Kok RM, Nolen WA, Heeren TJ (2007) Venlafaxine vs. nortriptyline in the treatment of elderly
depressed inpatients: a randomised, double-blind, controlled trial. Int J Geriatr Psychiatry
22:1247–1254.
<REFJ>Kok RM, Aartsen M, Nolen WA, Heeren T (2009) The course of adverse effects of nortriptyline
and venlafaxine in elderly patients with major depression. J Am Geriatr Soc 57:2112–2117.
<REFJ>Lecrubier Y, Bourin M, Moon CA, Schifano F, Blanchard C, Danjou P, Hackett D (1997) Efficacy
of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand 95:485–493.
<REFJ>Lemoine P, Guilleminault C, Alvarez E (2007) Improvement in subjective sleep in major
depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind
comparison with venlafaxine. J Clin Psychiatry 68:1723–1732.
<REFJ>Lepola U, Arato M, Zhu Y, Austin C (2003) Sertraline vs. imipramine treatment of comorbid panic
disorder and major depressive disorder. J Clin Psychiatry 64:654–662.
<REFJ>Lustman PJ, Clouse RE, Nix BD, Freedland KE, Rubin EH, McGill JB, Williams MM, Gelenberg
AJ, Ciechanowski PS, Hirsch IB (2006) Sertraline for prevention of depression recurrence in
diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry
63:521–529.
<REFJ>Luthringer R, Toussaint M, Schaltenbrand N, Bailey P, Danjou PH, Hackett D, Guichoux JY,
Macher JP (1996) A double-blind, placebo-controlled evaluation of the effects of orally
administered venlafaxine on sleep in inpatients with major depression. Psychopharmacol Bull
32:637–646.
<REFJ>Lydiard RB, Stahl SM, Hertzman M, Harrison WM (1997) A double-blind, placebo-controlled
study comparing the effects of sertraline vs. amitriptyline in the treatment of major depression. J
Clin Psychiatry 58:484–491.
<REFJ>Mahapatra SN, Hackett D (1997) A randomised, double-blind, parallel-group comparison of
venlafaxine and dothiepin in geriatric patients with major depression. Int J Clin Pract 51:209–213.
<REFJ>Malt UF, Robak OH, Madsbu HP, Bakke O, Loeb M (1999) The Norwegian naturalistic treatment
study of depression in general practice (NORDEP)-I: randomised double blind study. BMJ
318:1180–1184.
<REFJ>McPartlin GM, Reynolds A, Anderson C, et al. (1998) A comparison of once-daily venlafaxine XR
and paroxetine in depressed outpatients treated in general practice. Prim Care Psychiatry 4:127–
132.
<REFJ>Mehtonen OP, Sogaard J, Roponen P, Behnke K (2000) Randomized, double-blind comparison of
venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study
Group. J Clin Psychiatry 61:95–100.
<REFJ>Moller HJ, Glaser K, Leverkus F, Gobel C (2000) Double-blind, multicenter comparative study of
sertraline vs. amitriptyline in outpatients with major depression. Pharmacopsychiatry 33:206–212.
<REFJ>Montgomery SA, Huusom AK, Bothmer J (2004) A randomised study comparing escitalopram
with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology
50:57–64.
<REFJ>Moon CA, Jago W, Wood K, Doogan DP (1994) A double-blind comparison of sertraline and
clomipramine in the treatment of major depressive disorder and associated anxiety in general
practice. J Psychopharmacol 8:171–176.
<REFJ>Moscovitch A, Blashko CA, Eagles JM, Darcourt G, Thompson C, Kasper S, Lane RM (2004) A
placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective
disorder. Psychopharmacology (Berl) 171:390–397.
<REFJ>Munizza C, Olivieri L, Di Loreto G, Dionisio P (2006) A comparative, randomized, double-blind
study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
Curr Med Res Opin 22:1703–1713.
<REFJ>Nemeroff CB, Thase ME (2007) A double-blind, placebo-controlled comparison of venlafaxine
and fluoxetine treatment in depressed outpatients. J Psychiatr Res 41:351–359.
<REFJ>Nemeroff CB, Thase ME, Group ES (2007) A double-blind, placebo-controlled comparison of
venlafaxine and fluoxetine treatment in depressed outpatients. J Psychiatr Res 41:351–359.
<REFJ>Newhouse PA, Krishnan KR, Doraiswamy PM, Richter EM, Batzar ED, Clary CM (2000) A
double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin
Psychiatry 61:559–568.
<REFJ>O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, Zakhary B, Stough
WG, Arias RM, Rivelli SK, Krishnan R (2010) Safety and efficacy of sertraline for depression in
patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and
Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 56:692–699.
<REFJ>Olie JP, Gourion D, Montagne A, Rostin M, Poirier MF (2010) Milnacipran and venlafaxine at
flexible doses (up to 200▓mg/day) in the outpatient treatment of adults with moderate-to-severe
major depressive disorder: a 24-week randomized, double-blind exploratory study. Neuropsychiatr
Dis Treat 6:71–79.
<REFJ>Oslin DW, Ten Have TR, Streim JE, Datto CJ, Weintraub D, DiFilippo S, Katz IR (2003) Probing
the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline
and venlafaxine in depressed nursing home residents. J Clin Psychiatry 64:875–882.
<REFJ>Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA,
Froud DM, Raskin J, Thase ME (2008) A randomized, double-blind comparison of duloxetine and
venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res 42:22–34.
<REFJ>Pettinati HM, Oslin DW, Kampman KM, Dundon WD, Xie H, Gallis TL, Dackis CA, O’Brien CP
(2010) A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating
co-occurring depression and alcohol dependence. Am J Psychiatry 167:668–675.
<REFJ>Quednow BB, Kuhn KU, Stelzenmuelle R, Hoenig K, Maier W, Wagner M (2004) Effects of
serotonergic and noradrenergic antidepressants on auditory startle response in patients with major
depression. Psychopharmacology (Berl) 175:399–406.
<REFJ>Ravindran AV, Griffiths J, Merali Z, Anisman H (1995) Lymphocyte subsets associated with
major depression and dysthymia: modification by antidepressant treatment. Psychosom Med
57:555–563.
<REFJ>Rudolph RL, Feiger AD (1999) A double-blind, randomized, placebo-controlled trial of once-daily
venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord
56:171–181.
<REFJ>Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT (1998) A randomized,
placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major
depression. J Clin Psychiatry 59:116–122.
<REFJ>Rush AJ, Trivedi MH, Carmody TJ, Donahue RM, Houser TL, Bolden-Watson C, Batey SR,
Ascher JA, Metz A (2001) Response in relation to baseline anxiety levels in major depressive
disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology
25:131–138.
<REFJ>Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs
MM, Warden D, Luther JF, Shores-Wilson K, Niederehe G, Fava M (2006) Bupropion-SR,
sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:1231–1242.
<REFJ>Samuelian JC, Hackett D (1998) A randomized, double-blind, parallel-group comparison of
venlafaxine and clomipramine in outpatients with major depression. J Psychopharmacol 12:273–
278.
<REFJ>Sauer H, Huppertz-Helmhold S, Dierkes W (2003) Efficacy and safety of venlafaxine ER vs.
amitriptyline ER in patients with major depression of moderate severity. Pharmacopsychiatry
36:169–175.
<REFJ>Schatzberg A, Roose S (2006) A double-blind, placebo-controlled study of venlafaxine and
fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry 14:361–370.
<REFJ>Schneider LS, Nelson JC, Clary CM, Newhouse P, Krishnan KR, Shiovitz T, Weihs K (2003) An
8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly
outpatients with major depression. Am J Psychiatry 160:1277–1285.
<REFJ>Schweizer E, Feighner J, Mandos LA, Rickels K (1994) Comparison of venlafaxine and
imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 55:104–
108.
<REFJ>Sechter D, Troy S, Paternetti S, Boyer P (1999) A double-blind comparison of sertraline and
fluoxetine in the treatment of major depressive episode in outpatients. Eur Psychiatry 14:41–48.
<REFJ>Sheehan DV, Nemeroff CB, Thase ME, Entsuah R (2009) Placebo-controlled inpatient comparison
of venlafaxine and fluoxetine for the treatment of major depression with melancholic features. Int
Clin Psychopharmacol 24:61–86.
<REFJ>Silverstone PH, Ravindran A (1999) Once-daily venlafaxine extended release (XR) compared with
fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin
Psychiatry 60:22–28.
<REFJ>Silverstone PH, Salinas E (2001) Efficacy of venlafaxine extended release in patients with major
depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry 62:523–529.
<REFJ>Sir A, D’Souza RF, Uguz S, George T, Vahip S, Hopwood M, Martin AJ, Lam W, Burt T (2005)
Randomized trial of sertraline vs. venlafaxine XR in major depression: efficacy and
discontinuation symptoms. J Clin Psychiatry 66:1312–1320.
<REFJ>Smeraldi E, Rizzo F, Crespi G (1998) Double-blind, randomized study of venlafaxine,
clomipramine and trazodone in geriatric patients with major depression. Prim Care Psychiatry
4:189–195.
<REFJ>Sogaard J, Lane R, Latimer P, Behnke K, Christiansen PE, Nielsen B, Ravindran AV, Reesal RT,
Goodwin DP (1999) A 12-week study comparing moclobemide and sertraline in the treatment of
outpatients with atypical depression. J Psychopharmacol 13:406–414.
<REFJ>Stahl SM (2000) Placebo-controlled comparison of the selective serotonin reuptake inhibitors
citalopram and sertraline. Biol Psychiatry 48:894–901.
<REFJ>Suri RA, Altshuler LL, Rasgon NL, Calcagno JL, Frye MA, Gitlin MJ, Hwang S, ZuckerbrowMiller J (2000) Efficacy and response time to sertraline vs. fluoxetine in the treatment of unipolar
major depressive disorder. J Clin Psychiatry 61:942–946.
<REFJ>Thase ME, Rush AJ, Howland RH, Kornstein SG, Kocsis JH, Gelenberg AJ, Schatzberg AF,
Koran LM, Keller MB, Russell JM, Hirschfeld RM, LaVange LM, Klein DN, Fawcett J, Harrison
W (2002) Double-blind switch study of imipramine or sertraline treatment of antidepressantresistant chronic depression. Arch Gen Psychiatry 59:233–239.
<REFJ>Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA (2006) A doubleblind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant
efficacy, and tolerability. J Clin Psychopharmacol 26:482–488.
<REFJ>Thase ME, Gelenberg A, Kornstein SG, Kocsis JH, Trivedi MH, Ninan P, Li T, Pedersen R, Keller
M (2010) Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of
major depression: results from the PREVENT study. J Psychiatr Res 45:412–420.
<REFJ>Trick L, Stanley N, Rigney U, Hindmarch I (2004) A double-blind, randomized, 26-week study
comparing the cognitive and psychomotor effects and efficacy of 75▓mg (37.5▓mg b.i.d.)
venlafaxine and 75▓mg (25▓mg mane, 50▓mg nocte) dothiepin in elderly patients with moderate
major depression being treated in general practice. J Psychopharmacol 18:205–214.
<REFJ>Trivedi MH, Dunner DL, Kornstein SG, Thase ME, Zajecka JM, Rothschild AJ, Friedman ES,
Shelton RC, Keller MB, Kocsis JH, Gelenberg A (2010) Psychosocial outcomes in patients with
recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine
extended release. J Affect Disord 126:420–429.
<REFJ>Tzanakaki M, Guazzelli M, Nimatoudis I, Zissis NP, Smeraldi E, Rizzo F (2000) Increased
remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major
depression and melancholia. Int Clin Psychopharmacol 15:29–34.
<REFJ>Van Gurp G, Meterissian GB, Haiek LN, McCusker J, Bellavance F (2002) St John’s wort or
sertraline? Randomized controlled trial in primary care. Can Fam Physician 48:905–912.
<REFJ>Van Moffaert M, Bartholome F, Cosyns P, De Nayer AR, Mertens C (1995) A controlled
comparison of sertraline and fluoxetine in acute and continuation treatment of major depression.
Hum Psychopharmacol: Clin Exp 10:393–405.
<REFJ>Ventura D, Armstrong EP, Skrepnek GH, Haim Erder M (2007) Escitalopram vs. sertraline in the
treatment of major depressive disorder: a randomized clinical trial. Curr Med Res Opin 23:245–
250.
<REFJ>Wijkstra J, Burger H, van den Broek WW, Birkenhager TK, Janzing JG, Boks MP, Bruijn JA, van
der Loos ML, Breteler LM, Ramaekers GM, Verkes RJ, Nolen WA (2010) Treatment of unipolar
psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and
venlafaxine plus quetiapine. Acta Psychiatr Scand 121:190–200.
<REFJ>Wilson KC, Mottram PG, Ashworth L, Abou-Saleh MT (2003) Older community residents with
depression: long-term treatment with sertraline. Randomised, double-blind, placebo-controlled
study. Br J Psychiatry 182:492–497.
<REFJ>Wolkowitz OM, Wolf J, Shelly W, Rosser R, Burke HM, Lerner GK, Reus VI, Nelson JC, Epel
ES, Mellon SH (2011) Serum BDNF levels before treatment predict SSRI response in depression.
Prog Neuropsychopharmacol Biol Psychiatry 35:1623–1630.
<REFJ>Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E (1996) Double-blind controlled trial of
sertraline vs. paroxetine in the treatment of delusional depression. Am J Psychiatry 153:1631–
1633.
<REFJ>Zanardi R, Franchini L, Serretti A, Perez J, Smeraldi E (2000) Venlafaxine vs. fluvoxamine in the
treatment of delusional depression: a pilot double-blind controlled study. J Clin Psychiatry 61:26–
29.